Results 231 to 240 of about 1,873,173 (296)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Challenges and Methodologies to Assess Protein Requirement and Quality Across Different Life Stages in Dogs: A Review. [PDF]

Animals (Basel)
Scarpim LB, Pacheco LG.
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

ASAS-NANP symposium: mathematical modeling in animal nutrition: agent‑based modeling of nutrient requirements and growth performance in growing-finishing pigs for sustainable production systems. [PDF]

J Anim Sci
Rahimifar A, Kaniyamattam K, Wiegert JG, Tedeschi LO.   +3 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Developing Clinical Decision (Support) Systems Combining the Scientific and Regulatory Perspective: European Insights on Challenges, Requirements, and Practical Guidance.

JMIR Med Inform
Vrijlandt SEW, Janssen SWCM, van Rossum AMC, Achten NB, Oostenbrink R.   +4 more
europepmc   +1 more source

Prehospital blood transfusion coalition core competencies for emergency medical services personnel. [PDF]

Trauma Surg Acute Care Open
Krohmer J, O'Byrne H, Schaefer R, Bank EA, Holcomb JB, Bullock WJ, Hill RL, Levy M.   +7 more
europepmc   +1 more source

A Knowledge Graph Based Implicit Requirements Mining Method in Personalized Products Development

Zhenchong Mo, Lin Gong, Jun Gao, Haoran Cui, Junde Lan   +4 more
openalex   +2 more sources